Point Mutations in GLI3 Lead to Misregulation of its Subcellular Localization by Krauß, Sybille et al.
Point Mutations in GLI3 Lead to Misregulation of its
Subcellular Localization
Sybille Krauß
1,2, Joyce So
2, Melanie Hambrock
2, Andrea Ko ¨hler
3, Melanie Kunath
2, Constance Scharff
2,
Martina Wessling
4, Karl-Heinz Grzeschik
4, Rainer Schneider
2,3*, Susann Schweiger
2,5
1Charite ´ University Hospital, Department of Dermatology, Berlin, Germany, 2Max-Planck Institute for Molecular Genetics, Department of Human Molecular Genetics
(Ropers), Berlin, Germany, 3Institute of Biochemistry and Center for Molecular Biosciences Innsbruck (CMBI), Innsbruck, Austria, 4Center for Human Genetics, Phillipps
University, Marburg, Germany, 5Ninewells Hospital, Department of Neuroscience and Pathology, Dundee, United Kingdom
Abstract
Background: Mutations in the transcription factor GLI3, a downstream target of Sonic Hedgehog (SHH) signaling, are
responsible for the development of malformation syndromes such as Greig-cephalopolysyndactyly-syndrome (GCPS), or
Pallister-Hall-syndrome (PHS). Mutations that lead to loss of function of the protein and to haploinsufficiency cause GCPS,
while truncating mutations that result in constitutive repressor function of GLI3 lead to PHS. As an exception, some point
mutations in the C-terminal part of GLI3 observed in GCPS patients have so far not been linked to loss of function. We have
shown recently that protein phosphatase 2A (PP2A) regulates the nuclear localization and transcriptional activity a of GLI3
function.
Principal Findings: We have shown recently that protein phosphatase 2A (PP2A) and the ubiquitin ligase MID1 regulate the
nuclear localization and transcriptional activity of GLI3. Here we show mapping of the functional interaction between the
MID1-a4-PP2A complex and GLI3 to a region between amino acid 568-1100 of GLI3. Furthermore we demonstrate that
GCPS-associated point mutations, that are located in that region, lead to misregulation of the nuclear GLI3-localization and
transcriptional activity. GLI3 phosphorylation itself however appears independent of its localization and remains untouched
by either of the point mutations and by PP2A-activity, which suggests involvement of an as yet unknown GLI3 interaction
partner, the phosphorylation status of which is regulated by PP2A activity, in the control of GLI3 subcellular localization and
activity.
Conclusions: The present findings provide an explanation for the pathogenesis of GCPS in patients carrying C-terminal
point mutations, and close the gap in our understanding of how GLI3-genotypes give rise to particular phenotypes.
Furthermore, they provide a molecular explanation for the phenotypic overlap between Opitz syndrome patients with
dysregulated PP2A-activity and syndromes caused by GLI3-mutations.
Citation: Krauß S, So J, Hambrock M, Ko ¨hler A, Kunath M, et al. (2009) Point Mutations in GLI3 Lead to Misregulation of its Subcellular Localization. PLoS
ONE 4(10): e7471. doi:10.1371/journal.pone.0007471
Editor: Stefan Wo ¨lfl, Universita ¨t Heidelberg, Germany
Received May 8, 2009; Accepted September 22, 2009; Published October 15, 2009
Copyright:  2009 Krauß et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The project was financed by the DFG (Deutsche Forschungsgemeinschaft, SFB 577, project C04; Project SCHW 829/4-1) and the Volkswagen-Stiftung.
R.S. was supported by the Special Research Program SFB021-‘‘Cell Proliferation and Cell Death in Tumors’’ of the Austrian Science Fund (FWF). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rainer.schneider@uibk.ac.at
Introduction
GLI3 and two other GLI-proteins, GLI1 and GLI2, are
mammalian homologues of the Drosophila protein Cubitus inter-
ruptus (Ci), which is a transcriptional effector of Hedgehog (Hh)
signaling. Ci was shown to be part of a microtubule-associated
protein complex that also contains Fused (Fu), Suppressor of Fused
(SuFu) and Costal2 (Cos2). In absence of Hh signaling, Ci gets
phosphorylated by PKA and is subsequently cleaved by the
proteasome. The N-terminal cleavage product enters the nucleus
and acts as a transcriptional repressor of target genes. In the
presence of the Hh signal, this cleavage is blocked and Ci matures
into a transcriptional activator [1–4]. Similar to its Drosophila
homologue, GLI3 undergoes PKA-dependent cleavage and can
act as either a transcriptional activator or repressor of target genes
in the mammalian Sonic Hedgehog (SHH) pathway [5–10].
Among other genetic syndromes, mutations in GLI3 are
found in patients with Greig-cephalopolysyndactyly-syndrome
(GCPS [MIM175700]) [11,12], Pallister-Hall syndrome (PHS
[MIM146510]) [13,14] and - in one patient - acrocallosal
syndrome [MIM200990] [15]. Several studies have discussed
putative genotype-phenotype correlations to explain how muta-
tions in the same gene could cause clinically distinct syndromes.
While mutations leading to C-terminally truncated GLI3,
which functions as a constitutive repressor, are responsible for
the development of PHS [6,16], N-terminal loss-of-function
mutations lead to haploinsufficiency and cause GCPS [5,12,17].
However, in some cases of GCPS missense mutations in the C-
terminal part of GLI3 were observed that could not be
correlated with loss of function of the protein and therefore
did not seem to fit into this genotype-phenotype correlation
[11,13].
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7471Using several cancer cell lines, we have recently shown that
protein phosphatase 2A (PP2A) regulates the subcellular localization
and transcriptional activity of GLI3 [18]. An increase in PP2A
activity results in the cytosolic retention and decreased transcrip-
tional activity of GLI3, while inhibition of PP2A leads to nuclear
accumulation and increased transcriptionalactivity.Wehavefurther
seen that this mechanism is critically influenced by the MID1-a4-
ubiquitin-ligase complex that targets microtubule-associated PP2Ac
(catalytic subunit of PP2A) to ubiquitin-specific modification and
degradation [19]. Interestingly, the three GLI3-related conditions
GCPS, PHS and acrocallosal syndrome show phenotypic overlap
with Opitz BBB/G syndrome (OS [MIM300000 and 145410]), a
midline malformation syndrome caused by loss-of-function muta-
tions of MID1 [20]. While patients with GCPS share facial features
suchashypertelorismand broad nasal bridge with OS patients, PHS
patients can present with cleft lip/palate and laryngotracheal and
analmalformations,whichcanalsobefound inOSpatients.Patients
with acrocallosal syndrome however, similar to OS patients, can
show a full spectrum of midline malformations, including hypertel-
orism, broad nasal bridge, cleft lip/palate, congenital heart defects,
imperforate anus and hypospadias.
In this study, we have narrowed down the protein region of GLI3
that is necessary for its functional interaction with the MID1-a4-
PP2A complex. Furthermore, we show that missense mutations in
this region, as observed in GCPS and acrocallosal syndrome
patients, lead to changes in the subcellular localization of the GLI3
protein and interfere with its regulation by the MID1-a4-PP2A
complex. Our data give insight into a molecular cross-talk between
the MID1-a4-PP2A complex and GLI3, paving the way to a
molecular explanation for the loss-of-function phenotype in GCPS
patients with C-terminal missense mutations. In addition, they
provide evidence for a shared molecular mechanism underlying
severalmalformationsyndromeswithsignificantphenotypicoverlap.
Materials and Methods
Constructs
All expression-vector-constructs are listed in table 1. Sequences
of all mutants have been confirmed by direct sequencing.
Immunofluorescence
For immunofluorescence experiments, HeLa or U373MG cells
were plated on coverslips (in 6-well plates) at a density of 1610
5
cells per well one day before transfection. Cells were transfected
with the respective plasmids using Polyfect transfection reagent
(Qiagen) according to the manufacturer’s instructions. Twenty-
four hours after transfection, cells were fixed with 3.7%
paraformaldehyde in PEM buffer (106PEM contains 1 M Pipes,
0.05 M EGTA, 0.02 M MgCl2, pH 7.0). The GFP-GLI3 signal
distribution in individual cells occurred in three patterns:
exclusively nuclear fluorescence, even staining throughout the
cytosol and nucleus, or predominantly cytosolic fluorescence. 100
transfected cells per coverslip were counted and classified in one of
the three groups. Each experiment was repeated in triplicates.
Data shown represent mean 6 s.d. scored per group from 3
independent experiments of 100 cells each. Statistical significance
was evaluated using T-Test (two-tailed, homoscedastic). Micros-
copists were blinded to the nature of the constructs.
Transfection, cell fractionation and Western blotting
1610
5 HeLa cells per well of a 6-well plate were seeded 24 hours
prior transfection. Transfections with the respective plasmids were
Table 1. Vector-information and cloning strategies of all cDNA-expression constructs used in this study.
clone cDNA coding for/insert vector Enzymes used for cloning/strategy/publication
fpc18-1549 GLI3 AA 18-1549 pEGFP-C1 (Clontech) EcoRI-SmaI
fpn1-1522 GLI3 AA 1-1522 pEGFP-N1 (Clontech) Bsp120I-SacI
fpn1-396 GLI3 AA 1-396 pEGFP-N2 (Clontech) BamHI
fpn1-1100 GLI3 AA 1-1100 pEGFP-N3 (Clontech) SacI-SmaI
fpn824-1100 GLI3 AA 824-1100 fpn 1-1100 digested with EcoRI-Bsp120I, removal of a
2412 bp fragment (GLI3 aa 1-823), religation
fpc18-667 GLI3 AA 18-667 pEGFP-C1 (Clontech) EcoRI-Bsp120I
fpc18-828 GLI3 AA 18-828 pEGFP-C1 (Clontech) EcoRI-SmaI
fpc18-1100 GLI3 AA 18-1100 pEGFP-C1 (Clontech) EcoRI-SmaI
fpc568-1549 GLI3 AA 568-1549 fpc 18-1549 digested with BglII, removal of a 1756bp
fragment (GLI3 aa 18-585), religation
200-1580 GLI3 AA 200-1580 pEGFP-C1 (Clontech) SacI-SalI
400-1580 GLI3 AA 400-1580 pEGFP-C1 (Clontech) SacI-SalI
8x3 GLI-BS Luc 8 directly repeated copies of a GLI-binding site
(GAACACCCA)
pd51LucII [44] [45]
8x3 MutGLI-BS Luc 8 directly repeated copies of a mutant GLI-binding site
(GAAgtgggA)
pd51LucII [44] [45]
pRL Renilla luciferase pRL (Promega)
A934P GLI3 AA 18-1549 mutation A934P pEGFP-C1 (Clontech) Produced by in-vitro mutagenesis on fpc18-1549
I808M GLI3 AA 18-1549 mutation I808M pEGFP-C1 (Clontech) Produced by in-vitro mutagenesis on fpc18-1549
P707S GLI3 AA 18-1549 mutation P707S pEGFP-C1 (Clontech) Produced by in-vitro mutagenesis on fpc18-1549
MID1-myc MID1 complete cDNA pCMVTag3A (Stratagene) HinDIII-EcoRI
GLI3-Flag GLI3 AA 18-1580 pCMVTag2A (Stratagene) EcoRI
doi:10.1371/journal.pone.0007471.t001
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the manufacturer’s instructions. For cell fractionation, 48 hours
after transfection cells were resuspended in fractionation buffer
(40 mg/ml digitonin, 50 mM Tris-HCl, pH 7.5, 100 mM NaCl,
2.5 mM MgCl2) and incubated for 10 min at room temperature.
Nuclear and cytosolic fractions were separated by centrifugation
(1000 x g, 10 min, 4uC) and mixed with 26Magic Mix (48% urea,
15 mM Tris-HCl, 8.7% glycerol, 1% SDS, 0.004% bromphenol
blue, 143 mM b-mercaptoethanol). For analysis of total cell lysates
cells were resuspended in Magic Mix 48 hours after transfection.
Samples were denatured at 95uC, separated on SDS-Gels and
blotted on PVDF membranes (Roche).
Antibodies
All antibodies used in this study are listed in table 2.
RNAi
Twenty-four hours before transfection, HeLa cells were seeded
into 6-well plates at a density of 1610
5 per well. Cells were
transfected with 1.3 mg of synthetic siRNA per well using
Oligofectamine (Invitrogen) according to the manufacturer’s
instructions. Sequences of siRNA’s are listed (Table S1a).
Real-time PCR
Twenty-four hours before treatment, HeLa cells were seeded at a
density of 1610
5 cells per well of a 6-well plate. Cells were
transfected with siRNA’s as described. Total RNA was isolated
using an RNeasy Mini Kit (Qiagen) following the manufacturer’s
instructions. cDNA was synthesized using the TaqMan reverse
transcription reagents kit (Applied Biosystems) and real-time PCR
was carried out using the SYBRGreen PCR master mix (Applied
Biosystems) according to the manufacturer’s instructions with an
ABI7900HTcyclerunderthefollowingconditions:50uCfor2 min;
95uC for 10 min; 95uC for 15 sec, 60uC for 1 min for 40 cycles; and
95uC for 15 min, 60uC for 15 min, 95uC for 15 min for the
dissociation stage. Sequences of primers are listed (Table S1b).
Luciferase reporter assay
4610
4 HeLa cells per well of a 12-well plate were seeded
24 hours prior transfection. Reporter plasmids containing eight
either wildtype (wt) or mutant GLI binding sites linked to firefly
luciferase (1.5 mg DNA per well) were co-transfected with GLI3-wt
or mutant constructs (1 mg DNA per well) and renilla luciferase
(1 ng DNA per well) for normalization. Transfections with the
respective plasmids were performed using JetPEI (Polyplus
Transfections) according to the manufacturer’s instructions. The
reporter assays were carried out using the Dual-Luciferase
Reporter 1000 Assay System (Promega) following the manufac-
turer’s instructions. Luciferase intensities were measured in a
Centro Luminometer LB 960 (Berthold).
3D microscopy
For 3D microscopy experiments, HeLa cells were plated on
coverslips (in 6-well plates) at a density of 1610
5 cells per well one
day prior transfection. Cells were transfected with the respective
plasmids using Polyfect transfection reagent (Qiagen) according to
the manufacturer’s instructions. 24 hours after transfection cells
were fixed with 3.7% paraformaldehyde in PEM (106PEM
contains 1 M Pipes, 0.05 M EGTA, 0.02 M MgCl2, pH 7.0).
Afterwards cells were permeabilized with 0.2% TritonX100 and
blocked with 1% BSA. Antibody incubations were carried out
following the manufacturer’s instructions. 3D colocalization
studies were performed using an epifluorescence microscope
(Axioskop; Carl Zeiss MicroImaging, Inc.) equipped with a
100x-plan-neofluar oil-immersion lens (NA 1.35; Carl Zeiss
MicroImaging, Inc.) attached to a PIFOC z-SCAN (Physik
Instrumente), and a 12-bit CCD digital camera (SensiCam;
PCO) controlled by TILLvisION v4.0 software. Fluorochromes
were excited using a polychrome IV monochromator (T.I.L.L.
Photonics) in combination with a quadruple band pass beam
splitter and barrier filter (Chroma Technology Corp.) allowing
subsequent recording of blue (DAPI), red (Cy3), green (GFP)
fluorescence for the same focal plane. Spatial relationship of
protein signals was determined by interactively scanning through
the image stacks. Deconvolution was performed using the cMLE
algorithm of Huygens 2.1.4-essential (Scientific Volume Imaging)
running under Windows NT. Rendering of 3D data was done
using the Surpass module of Imaris 3.3.2 (Bitplane).
Confocal microscopy localization studies were performed using
an inverse laser scanning microscope (LSM510 META, Axiovert
200M) equipped with a 63x-plan-neofluar oil-immersion lens (Plan
Apochromat 63x/1.4oil) controlled by LSM510 4.0 SP2 (ZEISS)
software. Fluorescence signals were captured with the filters BP
505-530 for EGFP and BP 420-480 for DAPI. Images were
analyzed using the LSM Image Browser Version 4.2.0.121
(ZEISS).
2D-Gel electrophoresis
2D-Gel electrophoresis was carried out as described elsewhere
[21]. The following modifications were made to the protocol:
1.6610
6 HeLa cells were seeded in 150 cm
2 flasks 1 day prior
transfection. Cells were transfected using Polyfect (Qiagen) and
fractionated 48 hours after transfection in fractionation buffer
[10 mM Tris pH 7.5, 2.5 mM MgCl2, 10 mM DTT, PhosStop
(phosphatase inhibitor cocktail; Roche), complete (protease
inhibitor cocktail; Roche), 80 mg/ml Digitonin] as described (see
Western blot). Samples were treated with 500 U/ml benzonase
(Merck). Afterwards 4% Triton X-100, 9 M urea, and 0.4% mixed
ampholytes (composition see [21]) were added. IEF gels were
prepared as described [21] and run in a Mini Tube Gel Cell for 2-
D Electrophoresis (Bio-Rad) under the following conditions: 1 h
100 V; 1 h 200 V; 15 h 400 V; 1 h 600 V; 10 min 800 V; 5 min
1000 V. IEF gels were equilibrated (as described [21]) and
transferred to SDS gels which were run in a Mini-PROTEAN
Table 2. Antibodies used in this study.
antibody company
Catalogue
number publication
a4[ 1 9 ]
Actin SIGMA A2066
GAPDH Abcam Ab9485
Flag Stratagene 200471
Myc Clontech 3800-1
GFP Abcam Ab6673
GFP Roche 1814416
Cy3-anti-mouse Dianova 715-166-151
HRP-anti-mouse Dianova 115-035-003
HRP-anti-rabbit Amersham NA 9340
HRP-anti-goat Santa Cruz Sc-2020
phosphoserine sampler kit Biomol 54694
phosphothreonine sampler kit Biomol 54695
doi:10.1371/journal.pone.0007471.t002
Localization of GLI3-Mutants
PLoS ONE | www.plosone.org 3 October 2009 | Volume 4 | Issue 10 | e7471Tetra Electrophoresis System (Bio-Rad) at 200 V. Afterwards SDS
gels were subjected to Western blotting.
Phos-Tag
For mobility shift detection of phosphorylated proteins Phos-tag
technology (NARD Institute) was used. The acrylamide-pendant
Phos-tag ligand (#AAL-107) and MnCl2 were added to 6% w/v
acrylamide-gels in concentrations from 0 to 40 mM. Before blotting
gels were equilibrated first in Blotting buffer (50 mM Tris, 45 mM
Glycine, 0.04% SDS, 20% Methanol) containing 5 mM EDTA for
10 min and afterwardsinBlottingbufferwithout EDTAfor10 min.
Immunoprecipitation
For immunoprecipitation experiments, HeLa cells were plated in
75 cm
2 flasks at a density of 8610
5 one day prior transfection. Cells
were transfected with the respective plasmids using JetPEI
transfection reagent (Polyplus Transfections) according to the
manufacturer’s instructions. 48 hours after transfection cells were
lysed by sonication in IP-buffer [containing 50 mM Tris pH 7.5,
2.5 mM MgCl2, 100 mM NaCl, 1 mM DTT, PhosStop (phospha-
taseinhibitorcocktail;Roche),complete (protease inhibitorcocktail;
Roche)]. Immunoprecipitation was carried out using Protein A-
Agarose (Roche) following the manufacturer’s instructions.
Results
Subcellular localization and transcriptional activity of
GLI3 is regulated by the MID1-a4-PP2A complex
We have recently shown that the subcellular localization and
transcriptional activity of GLI3 is regulated by PP2A activity and
the MID1-a4 ubiquitin ligase complex in several cancer cell lines
with autonomously activated SHH-signaling. Endogenous GLI3 is
expressed in all these cell lines including HeLa (cervix carcinoma)
and U373MG (glioblastoma). In confirmation of these results, we
have now co-transfected GFP-GLI3 in HeLa cells either with
MID1- or a4-specific siRNA oligonucleotides and analyzed its
subcellular localization as described [18]. The transcriptional
activity of GLI3 was monitored by real-time PCR of the GLI3
target cyclin D1 and in a luciferase reporter assay. As shown in
Fig. 1a, over-expressed C-terminally GFP-tagged GLI3 localized
predominantly to the nucleus in 51% of transfected cells,
exclusively in the cytosol in 13% of cells, and showed a diffuse
pattern in 36% of transfected cells. To verify the precise
localization of GFP-GLI3 and the proper co-detection of nuclei
(DAPI) and nuclear protein we applied confocal microscopy,
showing comparable localization patterns as detected by epifluor-
escence (Figure S1). This is in line with our previous observations
[18]. Disruption of the MID1-a4-PP2A complex by RNAi-
mediated knock-down of endogenous a4 caused a significant
reduction in nuclear GLI3 localization (Fig. 1b). Concomitantly,
cells with diffuse and strictly cytosolic GLI3 were increased. The
cytosolic retention of GLI3 correlated with a reduced transcription
of its target gene cyclin D1 (Fig. 1c) and a decreased transcriptional
activity of GLI3 in a GLI3-reporter assay (Fig. 1d). To check the
specificity of the reporter assay for GLI3 transcriptional activity,
we used GFP tagged GLI3-deletion constructs, which either lack
the DNA-binding zinc-finger domains (constructs containing
amino acids 1-396, 824-1100), or a construct containing only
two out of the five zinc-finger domains (amino acids 568-1549).
While only weak induction of the GLI3 reporter by the deletion
constructs was observed, full-length GFP-GLI3 caused a signifi-
cant increase in reporter activity (Figure S2). To rule out the
possibility that the observed reduction of the GLI3-reporter after
a4-knockdown was caused by destabilization of the GFP-GLI3
protein, GFP-GLI3 was detected on a Western blot, showing no
differences in protein amounts after knockdown (Fig. 1d). The
efficiency of the knock-down procedure was proven by Western
blot detecting the a4 protein and Real-time-PCR amplifying the
a4 mRNA (Fig. 1e). Comparable results were obtained using
different, non-overlapping siRNA molecules and with N-termi-
nally tagged GLI3 constructs, indicating that the observed
localization effects are independent of target sequence and protein
cleavage (Table S2). Similarly, nuclear GFP-GLI3 was also
reduced after knock-down of the MID1 protein (Fig. 2a). Again,
cytosolic retention of GLI3 resulted in a decreased transcriptional
activity on its target gene cyclin D1 (Fig. 2b) and in a reduced
GLI3-reporter activity, without reduction of overall GFP-GLI3
protein levels (Fig. 2c). Knockdown efficiency was analyzed by
Western blot and Real-time-PCR (Fig. 2e).
Subcellular localization of mutant GLI3 proteins
In order to narrow down the protein region critical for MID1-
PP2A-dependent regulation of GLI3, we co-transfected several
GLI3 deletion mutants together with a4- or MID1-specific
siRNA’s. Using this approach, we have mapped the functional
interaction between the MID1-a4-PP2A complex and GLI3 to a
region between amino acid 568 and 1100 (Fig. 3).
Interestingly, some GCPS point mutations and a mutation in a
patient with acrocallosal syndrome are located in the identified
MID1-a4-PP2A complex-dependent regulation domain of GLI3
[A943P (as found in one patient with acrocallosal syndrome [15]),
I808M [11] and P707S [17] (as found in GCPS patients)]. These
point mutations could lead to a loss of the MID1-a4-PP2A
complex-regulated nuclear accumulation of GLI3. In order to
confirm this hypothesis, we introduced the three mutations into
the GFP-GLI3 protein and analyzed the mutant proteins for their
subcellular localizations. Compared to wt GFP-GLI3, a significant
reduction of cells with predominantly nuclear GFP-GLI3
localization (approximately 53% of wt GLI3 compared to 32%
of the mutants P707S, I808M, and A934P) was observed (Fig. 4a)
in HeLa cells. The same effect was seen in U373MG cells (Figure
S3). These results strongly suggest that the point mutations indeed
induce a misregulation of the subcellular localization of GLI3.
Furthermore, none of the mutant proteins reacted like wt GLI3
upon a4 or MID1 knock-down in HeLa cells (Fig. 4b). Again,
similar results were obtained in U373MG cells (Figure S4).
Point mutations lead to a reduced transcriptional activity
of GLI3
Misregulation of the subcellular localization of mutant GLI3
would be consistent with a reduction of its transcriptional activity.
In order to analyze effects of the point mutations on GLI3
transcriptional activity, we co-transfected GLI3 reporter plasmid
carrying either wild-type or mutated GLI binding sites with either
wt or mutant GFP-GLI3. Interestingly, the mutant GLI3 proteins
had significantly decreased capabilities to induce the luciferase
signal, suggesting that indeed the misregulated localization of
mutant GLI3 leads to a decrease in its transcriptional activity
(Fig. 5a). Equal transfection and synthesis efficiencies of the wt and
mutant GLI3-constructs were controlled on a Western blot
analyzing ratios of expressed GLI3 to GAPDH (Fig. 5b).
GLI3 partially colocalizes with the microtubule-associated
MID1-protein
Since we could show that subcellular GLI3-localization was
dependent on the microtubule-associated MID1-a4-PP2A com-
plex, we tested whether a co-localization of GLI3 and the
Localization of GLI3-Mutants
PLoS ONE | www.plosone.org 4 October 2009 | Volume 4 | Issue 10 | e7471Figure 1. Subcellular localization and transcriptional activity of GLI3 after a4-knockdown. (a) Subcellular distribution of GFP-GLI3 in HeLa
cells. Right: GFP signal distribution in individual cells occurred in three patterns: exclusively nuclear fluorescence (upper panel); even staining
throughout the cytosol and nucleus (middle panel); or predominantly cytosolic fluorescence (lower panel). Left: Transfected cells were randomly
chosen, counted and classified in one of the three groups. Data shown represent mean 6 s.d. scored per group from 3 independent experiments of
100 cells each. (b) Subcellular distribution of GFP-GLI3 in HeLa cells after co-transfection with either non-silencing control siRNA’s (left columns) or a4-
specific siRNA’s 3 and 4 (middle and right columns). The relative abundance of cells with exclusively nuclear GFP-GLI3 is shown in white columns,
even staining throughout the cytosol and nucleus is shown in gray columns and black columns represent cells with predominantly cytosolic
fluorescence. T-Test (two-tailed, homoscedastic): *p#0.0001. (c) Relative Cyclin D1 mRNA amounts in HeLa cells transfected with either non-silencing
control siRNA’s (white column) or a4-specific siRNA’s 3 and 4 (gray columns) as measured by real-time PCR. Columns represent mean values of 4
samples measured in parallel +/2 s.d. GAPDH was used for normalization. T-Test (two-tailed, homoscedastic): *p#0.00000001 (d) GLI3-reporter assay.
Left: Firefly-luciferase under the control of eight GLI-binding sites was co-transfected with a4- specific (gray columns) or control-siRNA’s (white
columns). As an internal transfection control renilla-luciferase was included and used for normalization. Columns show relative firefly-luciferase
signals from 4 samples 6 s.d. Right: Western blot of lysates from the GLI3-reporter assay. Similar expression levels of GFP-GLI3 in control and knock-
down samples are shown by detection with anti-GFP antibodies (lower panel). Loading of equal protein amounts is shown by Actin-staining (middle
panel). For knock-down control a4 was detected on the same membrane (upper panel). (e) Knock-down controls: Left: Knock-down efficiency of a4
(lanes 2 and 3) compared to a control treated with non-silencing siRNA’s (lane 1) is shown on a Western blot using an anti-a4 antibody (upper panel).
Loading of equal protein amounts is shown by Actin-staining (lower panel). Right: Effects of a4 siRNA’s compared to a control treated with non-
silencing siRNA’s on the endogenous a4 mRNA level as measured by real-time PCR. Columns represent mean values of 4 samples measured in parallel
+/2 s.d. GAPDH was used for normalization. T-Test (two-tailed, homoscedastic): *p#0.0000003.
doi:10.1371/journal.pone.0007471.g001
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PLoS ONE | www.plosone.org 5 October 2009 | Volume 4 | Issue 10 | e7471Figure 2.Subcellular localization and transcriptional activity of GLI3 after MID1-knockdown. (a) Subcellular distribution of GFP-GLI3 in
HeLa cells after co-transfection with either non-silencing control siRNA’s (left columns) or MID1-specific siRNA’s 8 and 10 (middle and right columns).
The relative abundance of cells with exclusively nuclear GFP-GLI3 is shown in white columns, even staining throughout the cytosol and nucleus is
shown in gray columns and black columns represent cells with predominantly cytosolic fluorescence. T-Test (two-tailed, homoscedastic): *p#0.001.
(b) Relative mRNA amounts of Cyclin D1 in HeLa cells transfected with either non-silencing control siRNA’s (white column) or MID1-specific siRNA’s 8
and 10 (gray columns) as measured by real-time PCR. Columns represent mean values of 4 samples measured in parallel +/2 s.d. GAPDH was used for
normalization. T-Test (two-tailed, homoscedastic): *p#0.0002 (c) GLI3-reporter assay. Left: Firefly-luciferase under the control of eight GLI-binding
sites was co-transfected with MID1- specific (gray columns) or control-siRNA’s (white columns). As an internal transfection control renilla-luciferase
was included and used for normalization. Columns show relative firefly-luciferase signals from 4 samples 6 s.d. Right: Western blot of lysates from the
GLI3-reporter assay. Similar expression levels of GFP-GLI3 in control and knock-down samples are shown by detection with anti-GFP antibodies (lower
panel). Loading of equal protein amounts is shown by GAPDH-staining (middle panel). For knock-down control endogenous MID1 was detected on
the same membrane (upper panel). (d) Knock-down controls: Left: Knock-down efficiency of MID1 specific (lanes 2 and 3) compared to non-silencing
siRNA’s (lane 1) on overexpressed Flag-tagged MID1 protein levels is shown on a Western blot using an anti-Flag antibody (upper panel). Loading of
equal protein amounts is shown by GAPDH-staining (lower panel). Right: Effects of MID1 siRNA’s compared to a control treated with non-silencing
siRNA’s on the endogenous MID1 mRNA level as measured by real-time PCR. Columns represent mean values of 4 samples measured in parallel +/2
s.d. GAPDH was used for normalization. T-Test (two-tailed, homoscedastic): *p#0.0002.
doi:10.1371/journal.pone.0007471.g002
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immunofluorescence. GFP-tagged GLI3 and myc-tagged MID1
were co-expressed in HeLa cells and visualized by Immunofluo-
rescence. Results show a locally restricted co-localization of GFP-
GLI3 and MID1-myc (Fig. 6) indicating a transient proximity of
both.
Phosphorylation of GLI3
Changes in PP2A activity result in misregulation of both - the
subcellular localization and transcriptional activity of GLI3. This
regulation could be mediated either by phosphorylation of the
GLI3 molecule itself (which would predict a different phosphor-
ylation pattern of nuclear and cytosolic GLI3) or by phosphor-
ylation of one of its interaction partners. To distinguish between
the two possibilities we analyzed the phosphorylation status of
GLI3. In a first set of experiments we tested if GLI3 is differentially
phosphorylated in dependency of its localization to the cytosol or
the nucleus by expressing Flag-GLI3 in HeLa cells. Nuclear and
cytosolic fractions were prepared, immunoprecipitated and
analyzed with a cocktail of anti-phospho-serine and -threonine
antibodies. As shown in Fig. 7a, serine/threonine phosphorylation
was detectable in both, the nuclear and cytosolic fraction. Purity of
the fractions was controlled by lamin A/C and tubulin detection.
To detect eventually differing phosphorylation patterns between
nuclear and cytosolic GLI3, 2D PAGE and Phos-Tag-SDS-PAGE
were performed: The isoelectric focusing pattern obtained in a 2D
PAGE analysis, which is highly sensitive to changes in phosphor-
ylation, showed an identical phosphorylation status of a GFP-
GLI3-construct (amino acids 568-1549) containing the PP2A-
dependent regulatory domain in both cellular compartments
(Fig. 7b). These results were confirmed by the analysis of total
lysates of full-length GFP-GLI3 expressing cells using the Phos-
Tag-technology, by which differentially phosphorylated protein-
isoforms can be separated by their molecular weight. On gels
containing increasing concentrations of the acrylamide-pendant
Phos-tag ligand only one GLI3 band was detected suggesting that
GLI3 is a mono-phosphorylated protein in the cell system used,
where PKA is not stimulated. Furthermore the separation of the
wt and mutant GFP-GLI3 constructs on Phos-tag-gels showed no
differences between wt and mutant GLI3-proteins (Fig. 7c). Taken
together these data strongly argue against the PP2A-dependent
regulation of GLI3 localization by its own phosphorylation
pattern, thereby suggesting the involvement of phospho-modified
co-factors.
Discussion
In this study, we demonstrate that the SHH target GLI3 is
regulated by a functional interaction between a MID1-a4-PP2A
complex-dependent regulation domain of GLI3 and the MID1-
a4-PP2A complex. Increased PP2A activity mediated by MID1 or
a4 knock-down resulted in the cytosolic retention of full-length
GLI3 and led to a reduced transcriptional activity. Interestingly,
GCPS- and acrocallosal syndrome-associated point mutations
within the MID1-a4-PP2A complex-dependent interaction do-
main led to a misregulation of the subcellular localization, a loss of
the MID1-a4-PP2A complex-dependent nuclear localization of
GLI3, and a reduction of the transcriptional activity of mutant
GLI3. As observed previously [18], the described mechanism
affects primarily the GLI3 transcriptional activator in our model
system.
The MID1-a4-PP2A complex regulates the nuclear
localization and transcriptional activity of the GLI3
activator
In this study, we have analyzed a functional interaction between
the MID1-a4-PP2A complex and the transcription factor GLI3. In
line with our previous results [18], changes in the subcellular
localization of GLI3 correlated changes in its transcriptional
activity. Transcriptional activity of GLI3 was measured by real-
time PCR analysis of the GLI3 target gene cyclin D1 and in a
luciferase reporter assay driven by a GLI3-dependent promoter.
Like its Drosophila homologue, Ci, GLI3 is known to be cleaved
into its repressor form in absence of SHH, whereas SHH signaling
represses cleavage, thereby promoting formation of full-length
GLI3 [6,22,23]. While the importance of the GLI3 repressor in
antagonizing SHH signaling has been well established, the role of
GLI3 as a transcriptional activator has been more controversially
Figure 3. Mapping of the GLI3-protein region critical for it’s MID1-PP2A-dependent regulation. Left: Schematic representation of the
functional domains of GLI3 and the deletion constructs used in this study. Right: Effects of MID1- or a4-knockdown on the nuclear localization of the
respective GLI3-deletion-construct. A significant decrease of nuclear GLI3 is indicated by +.
doi:10.1371/journal.pone.0007471.g003
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PLoS ONE | www.plosone.org 7 October 2009 | Volume 4 | Issue 10 | e7471Figure 4. Subcellular localization of mutant GFP-GLI3. (a) Subcellular distribution of wt and mutant GFP-GLI3 in HeLa cells. Visualization and
scoring were performed exactly as described in the legend to Fig. 1. The relative abundance of cells with exclusively nuclear GFP-GLI3 is shown in
white columns, even staining throughout the cytosol and nucleus is shown in gray columns and black columns represent cells with predominantly
cytosolic fluorescence. Data shown represent mean 6 s.d. scored per group from 3 independent experiments of 100 cells each. T-Test (two-tailed,
homoscedastic): *p#0.015. (b) Subcellular distribution of mutant GFP-GLI3 (upper panel mutant A934P, middle panel mutant I808M, lower panel
mutant P707S) in HeLa cells after cotransfection with a4- (right panel) or MID1-specific (left panel) siRNA’s. Visualization and scoring were performed
exactly as described in the legend to Fig. 1. The relative abundance of cells with exclusively nuclear GFP-GLI3 is shown in white columns, even
staining throughout the cytosol and nucleus is shown in gray columns and black columns represent cells with predominantly cytosolic fluorescence.
Data shown represent mean 6 s.d. scored per group from 3 independent experiments of 100 cells each. T-Test (two-tailed, homoscedastic): (p.0.1).
doi:10.1371/journal.pone.0007471.g004
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establish an important role for the GLI3 activator during
development [8,29–33]. In order to be able to distinguish between
effects of the GLI3 activator and those of the GLI3 repressor
peptides, we have chosen a tissue culture model in which GLI3
cleavage is reduced to a minimum and in which we had shown
autonomous SHH activation [18]. In this model system, changes
in the subcellular localization of GLI3 correlated with changes of
its transcriptional activity: a decrease of nuclear GLI3 protein led
to a reduction of transcriptional activity. In addition, transfection
of a luciferase reporter under the control of a GLI3-dependent
promoter together with wild-type GLI3 resulted in an increase in
reporter activity, while mutant proteins led to a much smaller
induction of the reporter, and knock-down of GLI3 in the model
system led to a reduction of target expression [18]. Furthermore
neither of the two deletion constructs that are quite similar to a
putative repressor form (Figure 3, constructs 18-667 and 18-828)
react on MID1 or a4 knock-down, which suggests that an intact
PP2A-dependent regulatory domain is necessary for MID1-a4-
PP2A complex regulation of the protein. In summary our data
suggest that the observed PP2A-MID1-dependent regulatory
mechanism primarily affects the GLI3 activator form.
The MID1-a4-PP2A complex functionally interacts with
amino acids 568-1100 of GLI3
Several functional domains have been described for the GLI3
protein. The N-terminus (amino acids 1-397) comprises the
repressor domain [22], followed by five zinc finger domains
(amino acids 480-632) and the cleavage site (amino acids 700-740)
[6,22]. An activation domain, which is responsible for the binding
of GLI3 to its co-activator CBP (CREB binding protein), spans
amino acids 827-1132 and includes multiple phosphorylation sites
[22]. Phosphorylation of amino acids 849, 865, 877, 907, 980 and
1106 by PKA and amino acids 861, 873 and 903 byGSK3b leads
to ubiquitination of GLI3 by SCF
bTrCP, followed by N-terminal
Figure 5. GLI3-reporter assay. (a) Firefly-luciferase under the control
of eight GLI-binding sites (normal or mutant for negative controls) was
co-transfected either with wt (white columns) or mutant (gray columns)
GFP-GLI3. As an internal transfection control renilla-luciferase was
included and used for normalization. Columns show relative firefly-
luciferase signals from 4 samples 6 s.d. (b) Western blot of lysates from
(a). Similar expression levels of wt and mutant GFP-GLI3 are shown by
detection with anti-GFP antibodies (upper panel). Loading of equal
protein amounts is shown by GAPDH-staining (lower panel).
doi:10.1371/journal.pone.0007471.g005
Figure 6. Colocalization of GFP-GLI3 and myc-MID1. Upper panel: Representative section of a HeLa cell cotransfected with GFP-GLI3 and myc-
MID1. A single focal plane of a deconvoluted 3D-image stack is shown. Yellow colour represents colocalization. Lower panel: Higher magnification of
the labelled sector from the upper panel and view from different angles to show that colocalization of GFP-GLI3 and myc-MID1 does not result from
random overlapping. Arrows point to the same signal in every picture. Angles are defined as indicated in the pictures.
doi:10.1371/journal.pone.0007471.g006
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nant domain), which is necessary for efficient cleavage, spans the
region from amino acid 648-915 [34]. The C-terminal end of the
GLI3 protein is characterized by the MBD (Mediator binding
domain), which links the full-length GLI3 to the Mediator
complex [35]. We have now mapped a PP2A-dependent
regulation domain to a region between amino acids 568-1100.
Regulation of GLI3 by the MID1-a4-PP2A complex could be
mediated either by modifying phosphorylation of GLI3 in its
PP2A-dependent regulation domain or by the phospho-specific
modification of a GLI3 cofactor binding to that region. All our
data however suggest PP2A-dependent modification of a GLI3
cofactor: (i) No differences in the phosphorylation pattern between
nuclear and cytosolic GLI3 could be detected either on one-
dimensional SDS-Gels with anti-serine and anti-threonine anti-
bodies as well as on 2D-gels, (ii) analysis of wild-type and mutants
GLI3 on Phos-tag gels suggest only one (probably phosphorylated)
GLI3 isoform in cells expressing either wild-type or mutants GLI3.
Figure 7. Phosphorylation of GLI3. (a) Left: GLI3-Flag was expressed in HeLa cells and isolated from nuclear or cytosolic fractions by
immunoprecipitation. Immunoprecipitates were analyzed by Western blot. Phosphorylation of GLI3-Flag was visualized by staining with a pool of
phospho-serine and phospho-threonine antibodies (upper panel). Afterwards the same membranes were stripped and incubated with Flag-
antibodies to verify that the phospho-specific bands co-stain with GLI3-flag (lower panel). Right: To control the efficiency of the fractionation
procedure, aliquots of the nuclear and cytosolic fractions were analyzed on Western blots with anti-LaminA/C- and anti-Tubulin-antibodies. (b)
Nuclear and cytosolic fractions of GFP-GLI3-AA568-1549 over-expressing HeLa cells were separated on 2D-Gels and blotted with an anti-GFP-
antibody. (c) Different concentrations of the acrylamide-pendant Phos-tag ligand (0, 5, 10, 20, 40 mM) have been added to 6% SDS-Gels that were
used to analyse GFP-GLI3, wild-type (wt) and mutant (A934P, I808M, P707S). An anti-GFP antibody has been used for detection.
doi:10.1371/journal.pone.0007471.g007
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cofactor.
C-terminal point mutations in GLI3 cause the same
phenotype as loss-of-function alleles
Mutations in the transcription factor GLI3 have been associated
with several phenotypes, including GCPS, PHS and - in one
patient - acrocallosal syndrome. While, loss-of-function mutations
that lead to a reduction of GLI3 protein and haploinsufficiency in
the patients are responsible for GCPS [5,12,17], truncating
mutations resulting in dominant negative effects and gain-of-
function of the repressor peptide cause PHS [6,16]. However,
some GCPS point mutations were discovered that do not lead to
an obvious loss of the protein, but rather produce a mutated
protein [11,13]. Until now, no clear mechanism by which a point
mutation in the C-terminal part of the protein could lead to the
GCPS loss-of function phenotype has been described.
Here, we show that the subcellular localization of GLI3 and its
transcriptional activity are regulated by the MID1-a4-PP2A
complex. We have mapped the domain that is responsible for
this regulatory interference to a novel PP2A-dependent regulation
domain on the GLI3 protein between amino acid 568 and 1100.
Some of the GCPS-associated point mutations in GLI3 localize to
this region. Analysis of some of these point mutants for their
intracellular localization pattern revealed that the mutant GLI3
proteins show abnormal subcellular localization and reduced
transcriptional activity. Furthermore, the PP2A-dependent regu-
lation of the subcellular localization was modified in the mutant
GLI3 proteins. Since the nuclear localization of full-length GLI3
protein is directly linked to its capacity as transcriptional activator,
the abnormal localization patterns of the mutant proteins point
towards a loss of nuclear GLI3 with subsequent decreased
activator function of the mutant GLI3 in patients.
Related ventral midline syndromes share disturbed GLI3
localization
As suggested previously (reviewed by [36]) phenotypic overlap
of syndromes in many cases point at shared molecular pathways of
the genes responsible for the syndromes, which makes phenotype
comparisons of monogenic syndromes a powerful tool to unravel
biochemical relationships. Our results suggest a molecular
mechanism underlying both the clinical similarities, as well as
the disparities, between three developmental disorders, OS, caused
by loss-of-function mutations in MID1 [20], GCPS, caused by
loss-of-function in one GLI3 allele [11,12], and PHS, caused by
expression of truncated GLI3 due to premature stop codon
formation [5,13,14]. Clinically, patients with all three syndromes
show disturbed midline development which, in the so-called
gliopathies (GCPS, PHS) is associated with limb malformations.
Patients with OS may present with hypertelorism, broad nasal
bridge, cleft lip and palate, laryngotracheal clefts, anal defects, and
hypospadias. GCPS patients may show symptoms like hypertel-
orism, broad nasal root, and limb abnormalities such as pre- and
postaxial polydactyly and syndactyly. PHS patients may present
with cleft lip, palate or uvula, laryngeal clefts and tracheal defects,
anal defects, and limb malformations like syn-, poly- or
oligodactyly. The net cellular response to SHH signaling appears
to be controlled by the relative abundance of full-length,
transcriptionally active GLI3 and a transcriptionally repressive
GLI3 cleavage fragment [5,8,10,29,33]. Our data show that full-
length GLI3, but not the N-terminal repressor peptide, is regulated
by MID1-PP2A. Based on the molecular aberrations underlying
each phenotype, the present data allow the formulation of a
unifying hypothesis to account for the overlap, but also some
disparities between the three syndromes (Fig. 8). In GCPS, one
full-length GLI3 allele is lost, causing a reduction of both activator
and repressor, resulting in apparent haploinsufficiency of GLI3
activator and repressor [11]. In PHS, truncating mutations cause
excess formation of repressor peptide, which acts in a dominant-
negative manner [5,13]. In OS, mutations in MID1 cause reduced
nuclear activator GLI3 products, resulting in overlap with the
haploinsufficiency in GCPS. Since only the full-length activator
form is removed from the nucleus, the net effect in OS is also an
excess nuclear abundance of GLI3 repressor, yielding phenotypic
overlap with PHS. Thus, while mutations in the target protein
GLI3 result in diverse phenotypes depending on the location of the
respective mutation, dysfunction of MID1 leads to a ‘compound’
syndrome. Interestingly, in an analysis using fully automated text
mining, Brunner et al. [36] have identified OS as the second
nearest phenotypic neighbor of PHS. Our data now fill the gap
between the phenotypic overlap of the two syndromes and possible
underlying molecular mechanisms by suggesting a biochemical
crosstalk between the involved gene products. In contrast to the
shared midline phenotypes, limb development is affected by loss-
of-function of GLI3 but rarely by MID1 mutations. This
difference might be either due to the fact that polydactyly
phenotypes, as seen in GCPS, are primarily caused by a loss of
GLI3-repressor, the regulation of which might be unaffected by
the MID1-a4-PP2A complex or it might reflect a fine-tuned,
tissue-specific regulation of the MID1 function and/or a
compensation of MID1 function by MID2 [19,37–40] in some
tissues. Thus, it might be that, due to as yet undefined
mechanisms, tissues that participate to the development of ventral
midline structures and their abnormalities are particularly sensitive
towards MID1 dysfunction. An important structure that might be
involved in the development of OS, GCPS and PHS phenotypes
are primary cilia. Their close association with microtubules and
growing evidence that intraflagellar transport and cilia develop-
ment play an important role in GLI3-processing and -signalling
[41,42], suggest that the MID1-a4-PP2A protein complex, which
is involved in microtubule-associated transport [43], could play a
role in the establishment or function of this structure. However,
the accumulation of PP2Ac in OS cells most likely does not lead to
a complete retention of GLI3 in the cytosol and, while insufficient
for the establishment of ventral midline structures, the residual
nuclear activity of GLI3 supports normal limb development.
In summary, our results give insight into a thus-far unknown
regulatory mechanism involving the MID1-a4-PP2A complex and
GLI3 in a human cell line model. However, further in vivo studies
are required to analyze the temporal and local regulation of these
interactions during development.
Supporting Information
Figure S1 Subcellular distribution of GFP-GLI3 in HeLa cells as
determined by confocal microscopy. GFP signal distribution in
individual cells occurred in three patterns: exclusively nuclear
fluorescence (e.g. as in cells marked by arrows, upper panel); even
staining throughout the cytosol and nucleus (e.g. as in cells marked
by stars, lower panel); or predominantly cytosolic fluorescence (e.g.
as in cells marked by arrowheads, upper panel). DAPI staining was
used to label nuclei.
Found at: doi:10.1371/journal.pone.0007471.s001 (5.71 MB TIF)
Figure S2 GLI3-reporter assay. Firefly-luciferase under the
control of eight GLI-binding sites (normal or mutant for negative
controls) was co-transfected either with full-length GFP-GLI3
(amino acids 18-1549) or GFP-GLI3 deletion constructs (amino
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PLoS ONE | www.plosone.org 11 October 2009 | Volume 4 | Issue 10 | e7471acids 1-396, 824-1100, or 568-1549). As an internal transfection
control renilla-luciferase was included and used for normalization.
The relative GLI3-reporter induction by over-expression of the
respective GFP-GLI3 constructs normalized to the respective
signal of the mutant GLI3-reporter is shown. Columns represent
signals from 3 samples 6 st.dev.
Found at: doi:10.1371/journal.pone.0007471.s002 (0.98 MB TIF)
Figure S3 Subcellular distribution of wildtype and mutant GFP-
GLI3 in U373MG cells. Visualization and scoring were performed
exactly as described in the legend to Fig. 1. The relative abundance
of cells with exclusively nuclear GFP-GLI3 is shown in white
columns, even staining throughout the cytosol and nucleus is shown
in gray columns and black columns represent cells with predom-
inantly cytosolic fluorescence. Data shown represent mean 6 s.d.
scored per group from 3 independent experiments of 100 cells each.
T-Test (two-tailed, homoscedastic): *p,0.0005.
Found at: doi:10.1371/journal.pone.0007471.s003 (1.39 MB TIF)
Figure S4 Subcellular distribution of mutant GFP-GLI3 (upper
panel mutant A934P, middle panel mutant I808M, lower panel
mutant P707S) in U373MG cells after cotransfection with alpha4-
or MID1-specific siRNA’s. Visualization and scoring were
performed exactly as described in the legend to Fig. 1. The
relative abundance of cells with exclusively nuclear GFP-GLI3 is
shown in white columns, even staining throughout the cytosol and
nucleus is shown in gray columns and black columns represent
cells with predominantly cytosolic fluorescence. Data shown
represent mean 6 s.d. scored per group from 3 independent
experiments of 100 cells each.
Found at: doi:10.1371/journal.pone.0007471.s004 (2.17 MB TIF)
Table S1 Table S1a: Sequences of siRNA’s used in this study.
Table S1b: Sequences of primers used for real-time PCR
experiments.
Found at: doi:10.1371/journal.pone.0007471.s005 (0.05 MB
DOC)
Table S2 Table S2 Summary of the subcellular localization of
GFP-GLI3 (N-terminally tagged) and GLI3-GFP (C-terminally
tagged) after knock-down of alpha4 using different siRNAs.
Visualization and scoring were performed exactly as described in
the legend to Fig. 1.
Found at: doi:10.1371/journal.pone.0007471.s006 (0.04 MB
DOC)
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